Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
An ionizable-lipid screening campaign produced an LNP formulation for dendritic-cell mRNA delivery. Researchers coencapsulated tumor-antigen mRNA, cyclic di-AMP, and manganese to coordinate antigen production with STING activation. The combination enhanced antigen presentation, tumor-specific T-cell responses, and antitumor activity in experimental models. It is a preclinical platform, with no demonstrated patient benefit in this report.
This study developed biologically assembled RNA delivery particles, termed RNA-BEVs, for topical skin applications. The vectors transferred functional mRNA into keratinocytes and reconstructed epidermis, enabling transient protein production. In diabetic rats, wound repair histology improved relative to the tested mRNA-LNP comparator. These biologically engineered vectors are a distinct carrier class, rather than conventional lipid nanoparticles.
Certara launched Bio Venture Catalyst, bringing together scientific development, regulatory, commercial, and investor-oriented strategy. The announcement includes model-informed development support and asset prioritization. The offering is a consulting service; its stated aims do not demonstrate improved clinical outcomes or guarantee financing.
LG AI Research and D&D Pharmatech signed a master agreement for next-generation oral peptide discovery, explicitly including macrocyclic peptides. The collaboration combines AI design with peptide development expertise. Named candidates, targets, financial terms, and human results were not disclosed. The agreement sets research objectives rather than demonstrating that oral absorption or clinical efficacy challenges have been solved.
Ironwood announced FDA approval of linaclotide for functional constipation in children ages 2 and older, extending the previous indication covering ages 6 and older. A 12-week, placebo-controlled Phase 3 trial in children ages 2–5 supported the decision, with improved spontaneous bowel-movement frequency at 72 micrograms. This concerns a gut-acting oral peptide, rather than systemic peptide delivery.
This perspective examines digital-twin claims against established pharmacometric practice. It argues that individual simulation, sequential updating, and decision-focused uncertainty analysis have longstanding roots in PK/PD modeling. The author emphasizes that fundamental limits, including identifiability, remain relevant despite new terminology.
20n Bio announced $7.5 million in Seed+ financing to advance AI-enabled cyclic peptide discovery, screening workflows, and its therapeutic pipeline. The company identifies oral peptides among potential applications but has not disclosed a validated clinical oral cyclic peptide candidate or human oral pharmacokinetics. The strategic lead investor was unnamed; investors from earlier rounds should not be assigned to this financing.
The authors reported a cryo-MicroED structure of cefadroxil, characterizing its molecular geometry, stereochemistry, and intermolecular packing. The crystallographic model also supported complementary molecular-dynamics analysis. This is a structural case study of an established beta-lactam antibiotic; the accompanying computational work should not be interpreted as clinical evidence of a new neurotherapeutic benefit or a general performance guarantee.
Hansoh presented two randomized, double-blind, placebo-controlled Phase 1 studies of HS-20118 involving 129 treated participants, including healthy volunteers and 23 patients with psoriasis. The company reported sustained pharmacokinetic and pharmacodynamic activity and early skin-response signals supporting exploration of weekly oral dosing. Small patient cohorts and short treatment duration limit conclusions about comparative efficacy and long-term safety.
BioAgilytix reviewed its earlier analytical investment in Morrisville and Hamburg, describing infrastructure for GMP QC, characterization, bioassays, release, and stability programs. This is a May 2026 company update about previously expanded capabilities, not a newly announced November facility opening or independent quality certification.
Merck announced a Science publication describing large-scale biocatalytic synthesis of enlicitide. Engineered enzymes enable peptide-fragment formation, coupling, and macrocyclization, combined with crystallization-based purification. The work addresses manufacturing of a complex orally available macrocyclic peptide. It provides a process-development example rather than new clinical efficacy evidence or a universally transferable route for every macrocycle.
Haisco disclosed clinical-trial clearance for HSK47388(I) tablets in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, while its psoriasis program was already in Phase 2. The filing describes preclinical effects in rat colitis models, not patient efficacy. This milestone expands authorized clinical development and is not marketing approval or confirmation of therapeutic benefit.
Continue your research
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.
